LabGenomics Signs MOU with U2 Medical Foundation for Specimen Consignment Business

LabGenomics, a global molecular and immunodiagnostics company, announced on March 24 that it has signed a memorandum of understanding (MOU) with its new consignment medical institution, U2 Medical Foundation, to collaborate on the specimen consignment business. Based on this agreement, the company aims to strengthen the stability of its testing operations and secure new revenue streams.

This partnership is considered a strategic decision to further enhance the continuity and operational stability of testing services, while also improving business competitiveness through a new cooperative framework. LabGenomics has responded to diverse testing demands by leveraging its accumulated technological expertise and sales network in the fields of molecular and immunodiagnostics. U2 Medical Foundation, on the other hand, possesses stable testing capabilities and operational infrastructure, which is expected to create significant synergies between the two organizations.

The company believes that this collaboration will boost the stability of its testing services and enable the establishment of a more flexible and efficient operational system. For existing clients, it will strengthen the stable provision of testing services, while for new clients, it will offer competitive services backed by reliable testing capabilities, which is expected to positively impact business expansion. In addition, both companies anticipate various benefits from their cooperation, including increased testing processing capacity, improved operational efficiency, and enhanced customer trust.

A LabGenomics representative stated, "We plan to swiftly finalize the main contract with U2 Medical Foundation within this month. This collaboration will be a significant turning point, not only bolstering the operational stability of our diagnostics business but also driving new revenue generation and expanding our testing capacity. We expect to see meaningful synergies in terms of customer trust and business competitiveness as LabGenomics’ business experience and market responsiveness are combined with U2 Medical Foundation’s stable testing infrastructure and operational capabilities."

The representative added, "Through this collaboration, we will not only establish a stable testing operation system but also continue to strengthen our foundation for mid- to long-term growth by expanding our cooperation to include competitive diagnostic services and a variety of new businesses in the future."

This content was produced with the assistance of AI translation services.